Eli Lilly Issues Warning , About Fake Weight-Loss Drugs ... Although compounding is legal amid drug shortages, the FDA has shared concerns about substandard products. . Eli Lilly says that ...

Eli Lilly & Co. (NYSE:LLY) has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling ...

Novo Nordisk has filed a citizen petition with the FDA to block the compounding of liraglutide, a key ingredient in its diabetes and obesity medications, by outsourcing facilities. The move ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make and sell copycat versions of its blockbuster drugs for weight loss until ...

As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.

Eli Lilly has filed lawsuits ... solutions for individual patient needs. The legal action also questions the safety of the compounded drugs and challenges whether the defendants are violating ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

You can reach Katie on Signal at palmer.01. Amid ongoing battles over alternate supplies of blockbuster weight loss drugs, Eli Lilly filed new lawsuits against four telehealth firms and their ...

Eli Lilly shares jumped 15% after a clinical trial ... of its obesity pill candidates in late 2023, citing tolerability issues. Novo Nordisk has also faced questions about the durability and ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan ... despite competitive and regulatory challenges. The pharma giant plans submissions to the Food & Drug Administration for obesity in late 2025 ...

This competition could potentially impact Eli Lilly’s market share and pricing power in the future. Despite these challenges, the company maintains strong fundamentals with a return on equity of ...